Rx00029 - Arsenic


Name:
Arsenic
Rx ID:
Rx00029
Validation Level:
Reference ID:
DB01169
Primary Indications:
Syphilis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Promyelocytic leukemia
Pathways:
Signal Transduction; FGF signaling pathway; Thyroid cancer - Homo sapiens (human); role of egf receptor transactivation by gpcrs in cardiac hypertrophy; Genes and (Common) Pathways Underlying Drug Add ...Click to show more
Drug Interactions:
Artemether; Lumefantrine; Quinupristin; Tacrolimus; Telavancin; Thiothixene; Toremifene; Trimipramine; Voriconazole; Vorinostat; ...
Click to show more...
Food Interactions:
No annotated food interactions in DrugBank.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00029
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Chemical, Pharmacological and Biological Annotations


ATC Code:
L01XX27
Categories:
Antineoplastic Agents; Homeopathic Agents
PubChem ID:
518740
KEGG Drug ID:
D02106
SMILE:
O1[As]2O[As]1O2
InChI:
1S/As2O3/c3-1-4-2(3)5-1
Classification:
Kingdom:
Inorganic Compounds
Superclass:
Mixed Metal/Non-metal Compounds
Class:
Metalloid Organides
Subclass:
Metalloid Oxides
Indication:
For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
Pharmacodynamics:
Arsenic Trioxide is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy.
Description:
Arsenic trioxide is a chemotheraputic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. Due to the toxic nature ...
Click to show more...
Mechanism:
The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells <i>in vitro</i>. Arsenic tri...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Ready biodegradable
Rat acute toxicity:
2.5942 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org